Catalent, Inc. (CTLT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Somerset, NJ, United States. El CEO actual es Alessandro Maselli.
CTLT tiene fecha de IPO 2014-07-31, 17,000 empleados a tiempo completo, cotiza en el NYSE, una capitalización de mercado de $11.52B.
Catalent, Inc. is a leading contract development and manufacturing organization that provides comprehensive solutions for drugs, biologics, cell and gene therapies, and consumer health products to pharmaceutical, biotechnology, and healthcare companies worldwide. Operating through four segments—Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services—the company offers specialized capabilities including softgel capsule manufacturing, biologic cell-line development, parenteral dose form production, oral delivery formulations, and clinical trial supply chain management. Its services span from early-stage formulation and development through commercial manufacturing and distribution, serving diverse markets including prescription and over-the-counter medications, dietary supplements, animal health products, and medical devices. Headquartered in Somerset, New Jersey, Catalent has established itself as a critical partner for companies seeking to bring innovative therapeutics and healthcare products to market efficiently and at scale.
